71 results about "Preeclampsia" patented technology

The invention discloses a pre-eclampsia prediction method and system based on machine learning and early pregnancy indexes. The pre-eclampsia prediction method comprises the following steps: acquiring early pregnancy laboratory index data and FMF model evaluation parameters of a to-be-predicted pregnant woman; based on a preset preeclampsia type, performing feature screening on the early pregnancy laboratory index data by using a Boruta algorithm to construct corresponding original features; inputting the original features into a trained first-level machine learning prediction model corresponding to the pre-eclampsia type to obtain a risk score; according to the risk score and an FMF model evaluation parameter, obtaining a joint feature; and inputting the joint features into a trained second-stage machine learning prediction model corresponding to the pre-eclampsia type to obtain a corresponding pre-eclampsia risk prediction result. According to the method, information of different sources and different physiological dimensions is deeply fused, analyzed and judged, and high-precision and low-cost early prediction of different pre-eclampsia types is realized.

The disclosure describes changes in cfRNA gene expression that are associated with risk for preeclampsia. Accordingly, the disclosure provides methods and kits for preeclampsia risk assessment.

The invention discloses a method and a system for predicting preeclampsia risk of a pregnant woman based on computer implementation. The method integrates the concentration level of vitamin D (especially 25-hydroxyvitamin D) in serum of pregnant women, angiogenesis biomarkers (such as sFlt-1 / PlGF ratio), conventional clinical indexes (such as mean arterial pressure and body mass index) and personal medical history data. A machine learning algorithm (such as a random forest or a gradient lifting model) is adopted to carry out weighted analysis on the multi-dimensional data, and a dynamic and high-precision prediction model is constructed. The system comprises a data acquisition module, an intelligent prediction module and a clinical decision support module, and can provide real-time risk assessment and personalized intervention suggestions (such as a vitamin D supplement scheme) for medical staff, so that early warning and effective management of preeclampsia are realized, and the risk of pregnancy outcome caused by maternal and infant poor pregnancy is reduced.

The invention provides a computer-implemented method for predicting and assessing a health risk parameter, such as the risk of diabetes, in particular gestational diabetes and / or preeclampsia, of a woman based on at least one pregnancy-related parameter, the method comprising the steps of: if the pregnancy-related parameter satisfies a first condition; if so, providing an assessment of the health risk parameter using a first machine learning model (1); providing an assessment of the health risk parameter using a second machine learning model (2) if the pregnancy-related parameter satisfies a second condition; and the health risk parameters are made available.

Provided are diagnostic and / or screening tests, assays and devices for preeclampsia (PE). The diagnostic and / or screening tests, assays and devices include test antibodies for activin A and / or inhibin A. The PE diagnostic and / or screening tests, assays and devices are capable of detecting activin A and / or inhibin A in a sample at a concentration of less than about 60 pg / mL. Corresponding methods of diagnosing and / or screening for PE are provided.

The invention provides an application of a pair of immune costimulatory factors TNFSF9 / TNFRSF9 as markers in preparation of a product for early prediction of preeclampsia, and the immune costimulatory factors comprise a tumor necrosis factor superfamily member 9 (TNFSF9) and a tumor necrosis factor receptor superfamily member 9 (TNFRSF9). The product is used for carrying out early warning on the preeclampsia occurrence risk 20 weeks before pregnancy. The product is used for detecting the immune costimulatory factor through at least one of serum, plasma, whole blood and placental tissue. The invention aims to improve the early prediction efficiency of preeclampsia by detecting the abnormal expression level of the pair of markers.

The invention discloses a machine learning-based pregnant woman preeclampsia subtype classification probability prediction method and system. According to the method, the one-carbon metabolic cycle core metabolite is combined with multi-source clinical indexes for the first time, and cross-modal deep feature fusion is realized by constructing derivative composite features with clear biological significance; in the model level, a double-layer self-adaptive model integration strategy is adopted, firstly, multiple base classifiers are subjected to self-adaptive weighted fusion based on cross validation performance, then further optimization is carried out through stacking generalization, and a final prediction model with high precision and high robustness is formed; besides, the system integrates SHAP interpretability analysis and risk positioning visualization based on historical distribution, not only outputs the classification probability, but also provides visual clinical decision-making assistance. According to the method, the problems of insufficient subtype identification ability, weak model generalization ability and poor result interpretability in the prior art are effectively solved, and reliable technical support is provided for health management and clinical decision-making in the gestation period.

The invention discloses a preeclampsia biomarker and an application of the preeclampsia biomarker. The preeclampsia biomarker comprises at least one of a fusion gene PSPC1-MRPS31P2 and a fusion gene LINC00630-AL035494. The preeclampsia biomarker can be used for detecting preeclampsia. The preeclampsia biomarker provided by the invention can provide a non-invasive diagnosis scheme for clinical prenatal preeclampsia, and preeclampsia specific high-expression fusion genes (PSPC1-MRPS31P2 and LINC00630-AL035494) in peripheral blood of a pregnant woman are detected through real-time quantitative PCR (Polymerase Chain Reaction), so that preeclampsia early prediction, disease diagnosis and monitoring of the state of a patient in the illness period are realized; and in combination with the existing clinical diagnosis scheme, the accuracy of pre-eclampsia diagnosis is improved.

The application provides use of zanamivir in preparation of a medicine for treating or preventing preeclampsia, and a corresponding medicine and treatment method; zanamivir can effectively improve high blood pressure, proteinuria, creatinine, neuraminidase and sialic acid elevation symptoms of preeclampsia, increase NO level, and improve pregnancy outcome. Zanamivir and hydroxyprogesterone caproate in combination show better effects.

The invention is suitable for the technical field of biology, and provides an L-NAME induced trophoblast organ injury model and a construction method and application thereof, and the construction method of the trophoblast organ injury model comprises the following steps: constructing a trophoblast organ by using human villus tissue; the method comprises the following steps: carrying out culture and passage treatment on a trophoblast organ, and then adding L-NAME with the final concentration of 15-60mM to carry out induced injury, so as to obtain the trophoblast organ injury model. The basic model used in the invention is a trophoblast-like organ which can be subcultured for a long time, so that the problems of difficult acquisition of placenta samples and ethics limitation in the clinical early stage are reduced. Meanwhile, L-NAME is used for performing drug-induced injury, a trophoblast organ injury model for simulating the placental pathological state of preeclampsia can be constructed, and compared with traditional hypoxia-induced injury, the method is more convenient, and the limitation of instruments and equipment is reduced.

The invention discloses application of C1INH in preparation of a product for prediction or auxiliary diagnosis of preeclampsia and the product, belongs to the technical field of biological medicines, and aims to detect the content of C1INH in a blood sample on a protein level by taking the blood sample of a subject as a detection object. According to the invention, C1INH molecules in blood are taken as a detection index, prediction and auxiliary diagnosis of preeclampsia of pregnant women can be realized, high sensitivity and specificity are realized, rapid detection can be realized, and a new way is provided for early screening and diagnosis of preeclampsia in the prior art.

This invention discloses a method, prediction method, and prediction device for constructing a preeclampsia prediction model based on temporal multimodal data, relating to the field of preeclampsia risk prediction technology. The construction method includes: acquiring multimodal temporal feature data of pregnant women with known pregnancy outcomes to construct a time-series dataset; the pregnant women with known pregnancy outcomes include those with and without preeclampsia; training a graph attention network and a fully connected network using the time-series dataset; embedding the resulting missing value fitting model as an embedding layer into a gated recurrent unit; and obtaining the preeclampsia prediction model after training with the time-series dataset. In this invention, the prediction model processes missing data through a missing value fitting model, effectively recovering missing information and ensuring the model can more accurately handle incomplete medical data. Simultaneously, the combination of a gated recurrent unit for capturing and predicting temporal features effectively improves the prediction accuracy of preeclampsia.

The present application relates to the technical field of medical data fusion processing, and discloses a method and system for predicting adverse pregnancy outcomes of preeclampsia by fusing placental microenvironment image features and serum biomarkers, wherein the method comprises: obtaining digital whole field image of placental tissue section and serum biomarker detection data at the same period; constructing a multi-modal sample data set; extracting multi-scale structure features of placental microenvironment; constructing serum biomarker discriminant features; dynamically fusing placental image features and serum marker features; constructing a prediction model for adverse pregnancy outcomes of preeclampsia and outputting a prediction probability. Compared with the prior art which only relies on single image information or single serum biomarker for risk assessment, it is difficult to realize stable prediction of the coordinated changes of placental microenvironment abnormalities and biochemical abnormalities. Due to the multi-scale image structure analysis, the model generalization ability for predicting adverse pregnancy outcomes of preeclampsia is improved.

The present invention includes methods and computer programs for use in the detection preeclampsia and / or determining an increased risk for preeclampsia in a pregnant female, the methods including identifying in a biosample obtained from the pregnant female cell-free DNA signals, including concentration, fetal fraction, and fragment size distribution. These methods provide for the identification of patients at risk of preeclampsia in the first trimester of pregnancy.

The application discloses a preeclampsia diagnosis and treatment biological marker and application thereof; the application deeply demonstrates the mechanism that high expression DHRS4 causes PE by inhibiting the invasiveness of trophoblasts from the clinical sample, cells and in vivo level, and overexpression DHRS4 in the application combines and up-regulates LONP2, degrades TFAM protein through ubiquitination, causes mitochondrial dysfunction, weakens the migration and invasion ability of trophoblasts, participates in the mechanism of PE occurrence, is a new mechanism clue obtained according to the pre-experiment results and information analysis, is a new target for deeply exploring the clinical diagnosis and treatment of PE, and the research result can provide a theoretical basis for guiding the early prediction and intervention of PE in the future.

The invention relates to a compound as shown in a formula (I), a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, pharmaceutically acceptable salt or prodrug of the compound, a preparation method of the compound, and a pharmaceutical composition of the compound and the stereoisomer, the tautomer, the isotope label, the nitrogen oxide, the solvate, the polymorphic substance and the pharmaceutically acceptable salt or prodrug. In particular, the compounds are NK-3 receptor antagonists, the compound can be used for preventing and / or treating depression, anxiety disorder, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory diseases, vomiting, pre-eclampsia, airway-related diseases, reproductive disorders, contraception and sex hormone dependent diseases, and can be used for preventing and / or treating diseases such as chronic bronchitis and chronic bronchitis. , gynecological diseases, and climacteric syndrome.

The present invention relates to a disease-specific biomarker for early prediction and diagnosis of preeclampsia and use thereof, and a composition for prediction or diagnosis of preeclampsia according to an aspect or a method of providing information for prediction or diagnosis thereof, can simply and effectively predict or diagnose the disease by measuring and comparing the mRNA level of a disease-specific protein or a gene encoding the protein changed in a patient.

This disclosure relates to improved detection of predictors of preeclampsia.

The invention provides a gene marker combination and application thereof in a risk prediction model of premature eclampsia. The gene marker combination comprises a combination selected from GTF2H1, CD48, PBX1, PLA2G2A, ACVR1B, HMGB1, ERBB2, XRCC5, TGFBR2, NFKB1, EGF, TLR6, EZH2, IKZF1, EGFR and CD36, a combination of HIPK1, MTHFR, IL6R, RAB27A, UBE2I, CREBBP, SOX8, HNF4A, ICOS, LIF, TMPRSS6, DNMT3A, WWTR1, RASSF1, FOXP1, TLR2 and MAPK14, AGRN, ATP2B1, ELAC2, HDAC5, GABARAP, FXR2, NFE2L2,

The application discloses a kind of based on HAPLN1 down-regulation induced preeclampsia animal model construction method and application of placental cell abnormal aging, belong to the field of biological medicine technology.The application can stably induce the animal model with typical preeclampsia clinical characteristics by reducing the expression level of HAPLN1 in pregnant mice, while reproducing the abnormal phenotype of placental cell aging.The method has strong controllability in operation process, and the model has good reproducibility, which can provide effective experimental tools for in-depth study of the pathogenesis of preeclampsia and development of new diagnosis and treatment strategies.

The application provides a marker for diagnosing preeclampsia, use of a reagent for detecting a CSRP2BP gene expression level in preparation of a kit, use of a preparation for improving the CSRP2BP gene expression level in preparation of a medicine, a non-treatment method for regulating migration ability and / or proliferation ability of trophoblasts, and a system for diagnosing preeclampsia, wherein the marker comprises a CSRP2BP gene. The CSRP2BP gene is used as the marker, the expression level of the CSRP2BP gene is detected, whether preeclampsia is suffered can be accurately judged, the diagnosis of preeclampsia is facilitated, and the application prospect is good.

The present application relates to a compound as shown in formula (I), stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, and preparation method and pharmaceutical composition. The compound is an NK-3 receptor antagonist, which can be used for preventing and / or treating depression, anxiety, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory disease, vomiting, preeclampsia, airway related disease, reproductive disorder, contraception and sex hormone dependent disease, gynecological disease related disease, menopausal syndrome related disease.

The application provides a construction method of a preeclampsia rat model with pregnancy and concurrent thrombocytopenia, relates to the technical field of disease animal model construction, and comprises the following steps: obtaining a pregnancy model by mating a pregnant female mouse with a male mouse; injecting an adenovirus into the uterus of the model group pregnant female mouse in the pregnancy cycle of the pregnancy model, and injecting a carrier virus into the control group; and observing and measuring typical clinical characteristics of preeclampsia of the rat. After being verified by a systematic preeclampsia animal model evaluation method, the preeclampsia-like mouse constructed by the method has typical clinical characteristics of preeclampsia such as thrombocytopenia, is highly similar to the performance of a preeclampsia patient, has good clinical symptom simulation, and is of great significance for in-depth study of the cause, occurrence and development mechanism and treatment scheme of PE.

The invention discloses a human placenta organoid gene intervention method based on lentivirus transfection, and belongs to the technical field of biological medicine. According to the method, key parameters of lentivirus transfection, namely the volume ratio of cell suspension to lentivirus to DMEM (Dulbecco Modified Eagle Medium) of 10: 2: 40 and the optimal transfection time of 4 hours, are optimized and determined, so that high transfection efficiency is ensured, the adverse effect of the virus on the activity of the organoid is remarkably reduced, and good organoid balling capacity and normal growth state are maintained. According to the invention, stable and controllable gene intervention is realized in a three-dimensional organoid model which highly simulates the structure and function of a human placenta for the first time, and the obtained placenta organoid subjected to gene intervention has a great significance for deeply researching the molecular mechanism of placenta development in a highly bionic in-vitro environment and exploring the pathogenesis of pregnancy-related diseases such as preeclampsia and the like. And an ideal research platform which is reliable and close to the physiological state is provided by screening or evaluating intrauterine gene therapy strategies.

The present invention includes methods and materials for use in the detection preeclampsia and / or determining an increased risk for preeclampsia in a pregnant female, the method including identifying in a biosample obtained from the pregnant women a plurality of circulating RNA (C-RNA) molecules.

A noninvasive blood-based biopsy measures surface protein receptors on specific circulating cell populations. Dysregulated quantities of specific surface protein receptors on specific circulating cells indicate the diseased tissue origin. Thus, specific circulating cells serve as proxies for diseased tissue cells as they are shed from such tissues. This approach can be used not only for preeclampsia but also for other vascular disorders where detecting surface protein receptors associated with particular disorders can increase sensitivity and disease specificity. Detection of a high level VEGFR1 on isolated circulating cells that are immunopositive for CD34 and CD31 can be used to identify and treat subjects suffering from preeclampsia.

The application discloses a kind of preeclampsia (Preeclampsia, PE) diagnosis and treatment biology marker and its application;The application is from clinical sample, cell and in-depth demonstration of overexpressed FBP2 at the level of body, which causes the mechanism of PE occurrence by inhibiting the invasion of trophoblasts, and the application verifies that the classic gene HEY1 downstream of NOTCH3 can be combined with the promoter region of FBP2 and transcribe to inhibit the expression of FBP2, FBP2 is combined with c-MYC protein and inhibits the transcriptional activity of c-MYC, down-regulates the transcriptional expression of TFAM, causes mitochondrial dysfunction, weakens the migration and invasion ability of trophoblasts, participates in the mechanism of PE occurrence, is a new mechanism clue obtained according to the results of pre-experiment and information analysis, is a new target for in-depth exploration of PE clinical diagnosis and treatment, and the research results can provide theoretical basis for guiding early prediction and intervention of PE in the future.

The invention discloses a traditional Chinese medicine composition for preventing and treating pregnancy complications as well as a preparation method and application thereof. The composition is composed of medicinal and edible traditional Chinese medicines including radix rehmanniae recen, fructus gardeniae, gastrodia elata, fructus lycii and exocarpium citri rubrum, and mulberry leaves, ramulus uncariae cum uncis and the like can be selectively added. The preparation method comprises the steps of extracting volatile oil by steam distillation, leaching by a solvent, concentrating, mixing and the like, and can be combined with ultrasonic crushing to strengthen extraction. The composition is based on the treatment method of nourishing kidney, containing wood, clearing heat, calming liver, dissolving turbidity and preventing miscarriage in traditional Chinese medicine, has the effects of multi-target synergistic pressure reduction, proteinuria improvement and fetal development promotion aiming at the pathogenesis of yin deficiency and yang hyperactivity in the gestation period, is high in safety and free of fetal toxic and side effects, and is suitable for prevention and treatment of hypertensive diseases in the gestation period such as preeclampsia and the like.

A method and device for measuring intra-abdominal pressure in a pregnant woman to assess likelihood or occurrence of pre-eclampsia. The method includes providing a catheter having first and second lumens and a balloon, inserting the catheter into a bladder of the patient, injecting gas into the first lumen of the catheter to expand the balloon, obtaining a first pressure reading of the bladder based on deformation of the balloon to thereby monitor pressure within an abdomen of the mother to assess if pre-eclampsia is occurring or likely to occur and transmitting the first pressure reading to an external monitor connected to the catheter. The pressure reading is indicative of the presence and / or risk of pre-eclampsia to determine when intervention should occur to prevent morbidity and mortality of the woman and baby.

A method for assessing the risk of preeclampsia in a pregnant subject is provided. The method can comprise: obtaining at least one blood pressure pulse waveform from at least one arterial site of the subject; determining a risk of preeclampsia in the subject, based at least in part on the at least one blood pressure pulse waveform; and generating an output indicative of the determined risk.